These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 10532639)

  • 1. A comparison of 11C-labeled L-DOPA and L-fluorodopa as positron emission tomography tracers for the presynaptic dopaminergic system.
    Torstenson R; Tedroff J; Hartvig P; Fasth KJ; Långström B
    J Cereb Blood Flow Metab; 1999 Oct; 19(10):1142-9. PubMed ID: 10532639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional brain kinetics of 6-fluoro-(beta-11C)-L-dopa and (beta-11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography.
    Hartvig P; Lindner KJ; Tedroff J; Bjurling P; Hörnfelt K; Långström B
    J Neural Transm Gen Sect; 1992; 87(1):15-22. PubMed ID: 1536715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin on in vivo L-[beta-11C]dopa turnover in the rat striatum with infusion of L-tyrosine.
    Tsukada H; Lindner KJ; Hartvig P; Tani Y; Bjurling P; Kihlberg T; Westerberg G; Watanabe Y; Långström B
    J Neural Transm Gen Sect; 1994; 95(1):1-15. PubMed ID: 7857582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-DOPA modulates striatal dopaminergic function in vivo: evidence from PET investigations in nonhuman primates.
    Tedroff J; Torstenson R; Hartvig P; Lindner KJ; Watanabe Y; Bjurling P; Westerberg G; Långström B
    Synapse; 1997 Jan; 25(1):56-61. PubMed ID: 8987148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reproducibility of striatal uptake data obtained with positron emission tomography and fluorine-18-L-6-fluorodopa tracer in non-human primates.
    Pate BD; Snow BJ; Hewitt KA; Morrison KS; Ruth TJ; Calne DB
    J Nucl Med; 1991 Jun; 32(6):1246-51. PubMed ID: 1904482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of regional cerebral utilization of [11C]-L-3,4-dihydroxy-phenylalanine (DOPA) in the primate by positron emission tomography.
    Tedroff J; Aquilonius SM; Hartvig P; Lundqvist H; Bjurling P; Långström B
    Acta Neurol Scand; 1992 Mar; 85(3):166-73. PubMed ID: 1574997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine.
    Doudet DJ; Chan GL; Jivan S; DeJesus OT; McGeer EG; English C; Ruth TJ; Holden JE
    J Cereb Blood Flow Metab; 1999 Mar; 19(3):278-87. PubMed ID: 10078880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of radiotracers in human plasma during positron emission tomography.
    Cumming P; Yokoi F; Chen A; Deep P; Dagher A; Reutens D; Kapczinski F; Wong DF; Gjedde A
    Synapse; 1999 Nov; 34(2):124-34. PubMed ID: 10502311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of an 18F-labeled dopa prodrug as a PET tracer for studying brain dopamine metabolism.
    Ishiwata K; Shinoda M; Ishii S; Nozaki T; Senda M
    Nucl Med Biol; 1996 Apr; 23(3):295-301. PubMed ID: 8782240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
    Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
    Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.
    Guttman M; Léger G; Reches A; Evans A; Kuwabara H; Cedarbaum JM; Gjedde A
    Mov Disord; 1993 Jul; 8(3):298-304. PubMed ID: 8341294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
    Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H
    J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The transport of L-6-fluorodopa and its metabolites from blood to cerebrospinal fluid and brain.
    Hammerstad JP; Pate BD; Hewitt KA; Chan GL; Ruth TJ; Calne DB
    Ann Neurol; 1993 Oct; 34(4):603-8. PubMed ID: 8215248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin and infusion of L-tyrosine on the in vivo L-[beta-11C] DOPA disposition in the monkey brain.
    Tsukada H; Lindner KJ; Hartvig P; Tani Y; Valtysson J; Bjurling P; Kihlberg T; Westerberg G; Watanabe Y; Långström B
    Brain Res; 1996 Mar; 713(1-2):92-8. PubMed ID: 8724979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.
    Sawle GV; Burn DJ; Morrish PK; Lammertsma AA; Snow BJ; Luthra S; Osman S; Brooks DJ
    Neurology; 1994 Jul; 44(7):1292-7. PubMed ID: 8035933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
    Cumming P; Gjedde A
    Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling of fluorine-18-6-fluoro-L-Dopa in humans.
    Wahl L; Nahmias C
    J Nucl Med; 1996 Mar; 37(3):432-7. PubMed ID: 8772639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral 6-[(18)F]fluoro-L-DOPA (FDOPA) metabolism in pig studied by positron emission tomography.
    Danielsen EH; Smith DF; Gee AD; Venkatachalam TK; Hansen SB; Hermansen F; Gjedde A; Cumming P
    Synapse; 1999 Sep; 33(4):247-58. PubMed ID: 10421705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
    Lee CS; Samii A; Sossi V; Ruth TJ; Schulzer M; Holden JE; Wudel J; Pal PK; de la Fuente-Fernandez R; Calne DB; Stoessl AJ
    Ann Neurol; 2000 Apr; 47(4):493-503. PubMed ID: 10762161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity.
    Tedroff J; Torstenson R; Hartvig P; Sonesson C; Waters N; Carlsson A; Neu H; Fasth KJ; Långström B
    Synapse; 1998 Apr; 28(4):280-7. PubMed ID: 9517836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.